Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies.
Pathog Immun
; 7(1): 95-103, 2022.
Article
in English
| MEDLINE | ID: covidwho-1924851
ABSTRACT
Background:
Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and treatment on the development and persistence of Long COVID have intensified.Methods:
We report 4 sequential cases from a post-COVID cohort study demonstrating variability in outcomes following differentially timed nirmatrelvir therapy, received as part of clinical care.Results:
In the first case, the participant experienced symptomatic rebound and developed Long COVID despite early initiation of antiviral therapy. In the next 2 cases, participants reported improvement in persistent COVID symptoms when nirmatrelvir was taken 25 and 60 days following initial symptom onset. In the final case, an individual with presumed Long COVID for 2 years reported substantial improvement in chronic symptoms when taking nirmatrelvir following SARS-CoV-2 re-infection.Conclusions:
These anecdotes suggest that systematic study of antiviral therapy for Long COVID is warranted.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Systematic review/Meta Analysis
Topics:
Long Covid
/
Vaccines
/
Variants
Language:
English
Journal:
Pathog Immun
Year:
2022
Document Type:
Article
Affiliation country:
Pai.v7i1.518
Similar
MEDLINE
...
LILACS
LIS